Clinical trial

APG-1252 in Patients With SCLC or Advanced Solid Tumors

NCT03387332

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2017-12-01

PhasePHASE1

Study timeline

Study start (actual)2017-12-01Date precision: day

Registry last updated2021-08-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Small Cell Lung Cancer and Other Solid Tumorsunresolved

Interventions

APG-1252DRUG

Sponsors & collaborators

Ascentage Pharma Group Inc.lead sponsor

Suzhou Yasheng Pharmaceutical Co., Ltd.collaborator

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03387332 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.